全文获取类型
收费全文 | 1976506篇 |
免费 | 140486篇 |
国内免费 | 3987篇 |
学科分类
医药卫生 | 2120979篇 |
出版年
2018年 | 18901篇 |
2016年 | 16079篇 |
2015年 | 18428篇 |
2014年 | 25960篇 |
2013年 | 39708篇 |
2012年 | 53857篇 |
2011年 | 57703篇 |
2010年 | 34546篇 |
2009年 | 32641篇 |
2008年 | 55552篇 |
2007年 | 59723篇 |
2006年 | 60626篇 |
2005年 | 59400篇 |
2004年 | 57041篇 |
2003年 | 55370篇 |
2002年 | 54507篇 |
2001年 | 88083篇 |
2000年 | 90524篇 |
1999年 | 77323篇 |
1998年 | 21912篇 |
1997年 | 19805篇 |
1996年 | 19930篇 |
1995年 | 18711篇 |
1994年 | 17809篇 |
1993年 | 16641篇 |
1992年 | 61853篇 |
1991年 | 60453篇 |
1990年 | 59454篇 |
1989年 | 57533篇 |
1988年 | 53724篇 |
1987年 | 52696篇 |
1986年 | 50420篇 |
1985年 | 48143篇 |
1984年 | 36063篇 |
1983年 | 31087篇 |
1982年 | 18678篇 |
1981年 | 16426篇 |
1979年 | 34056篇 |
1978年 | 23944篇 |
1977年 | 20520篇 |
1976年 | 19424篇 |
1975年 | 21359篇 |
1974年 | 25266篇 |
1973年 | 24303篇 |
1972年 | 23124篇 |
1971年 | 21514篇 |
1970年 | 20248篇 |
1969年 | 19215篇 |
1968年 | 18229篇 |
1967年 | 16289篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
E. Niclas Jonsson Rujia Xie Scott F. Marshall Rosalin H. Arends 《British journal of clinical pharmacology》2016,81(4):688-699
AimsThe aims were to 1) develop the pharmacokinetics model to describe and predict observed tanezumab concentrations over time, 2) test possible covariate parameter relationships that could influence clearance and distribution and 3) assess the impact of fixed dosing vs. a dosing regimen adjusted by body weight.MethodsIndividual concentration–time data were determined from 1608 patients in four phase 3 studies conducted to assess efficacy and safety of intravenous tanezumab. Patients received two or three intravenous doses (2.5, 5 or 10 mg) every 8 weeks. Blood samples for assessment of tanezumab PK were collected at baseline, 1 h post‐dose and at weeks 4, 8, 16 and 24 (or early termination) in all studies. Blood samples were collected at week 32 in two studies. Plasma samples were analyzed using a sensitive, specific, validated enzyme‐linked immunosorbent assay.ResultsA two compartment model with parallel linear and non‐linear elimination processes adequately described the data. Population estimates for clearance (CL), central volume (V
1), peripheral volume (V
2), inter‐compartmental clearance, maximum elimination capacity (VM) and concentration at half‐maximum elimination capacity were 0.135 l day–1, 2.71 l, 1.98 l, 0.371 l day–1, 8.03 μg day–1 and 27.7 ng ml–1, respectively. Inter‐individual variability (IIV) was included on CL, V
1, V
2 and VM. A mixture model accounted for the distribution of residual error. While gender, dose and creatinine clearance were significant covariates, only body weight as a covariate of CL, V
1 and V
2 significantly reduced IIV.ConclusionsThe small increase in variability associated with fixed dosing is consistent with other monoclonal antibodies and does not change risk : benefit. 相似文献
15.
16.
17.
18.
F. Fruzzetti G. Palla A. Sbrana T. Simoncini M. R. Sessa 《Gynecological endocrinology》2020,36(10):938-940
AbstractObjective: To understand the origin of extremely high gonadotropin levels in a perimenopausal woman.Methods: A 52-year-old woman with a 2?months of amenorrhea followed spontaneous menstrual cycles recovery was referred to our outpatient clinic with elevated follicle-stimulating hormone (FSH, 483 mUI/ml), luteinizing hormone (LH, 475 mUI/ml) and prolactin (PRL, 173?ng/ml). She was known to take levosulpiride. The gonadotropin levels did not fit with the clinical features.Results: A gonadotroph tumor was ruled out. Further analysis confirmed constantly high FSH, LH and PRL levels. The measurements were repeated using different analytical platforms with different results. After serial dilutions, nonlinearity was present suggesting an immunoassay interference. After post-polyethylene glycol recovery, hormone levels appeared in the normal range. Anti-goat antibodies were recognized in the serum of the patient.Conclusions: This case report shows a case of falsely abnormal high gonadotropin and PRL levels in a woman during menopause transition. In the clinical practice the evaluation of gonadotropin profile is not recommended at this age, but the abnormal levels stimulated further evaluation. An interference in the assay due to anti-goat antibodies resulted in abnormally high level of FSH and LH. A strict collaboration between clinicians and the laboratory is needed, when laboratory findings do not correspond to clinical findings. 相似文献
19.
20.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600